![PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users](https://i1.rgstatic.net/publication/355710507_Evaluation_of_the_abuse_potential_of_difelikefalin_a_selective_kappa-opioid_receptor_agonist_in_recreational_polydrug_users/links/617aa6713c987366c3f63e00/largepreview.png)
PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users
![PDF) Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors | Todd Vanderah and Frédérique Menzaghi - Academia.edu PDF) Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors | Todd Vanderah and Frédérique Menzaghi - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/41635213/mini_magick20190218-18590-1wvwz4f.png?1550559402)
PDF) Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors | Todd Vanderah and Frédérique Menzaghi - Academia.edu
![Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - JAAD International Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - JAAD International](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d7e9437a-10fe-4493-bb0a-b928662d11bd/gr1.jpg)
Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications - JAAD International
![Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/375/2/332/F1.large.jpg)
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
![Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/375/2/332/F2.large.jpg)
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ff659c0a-df99-4a5e-8df9-c1e1925ea7d0/jcpt12404-fig-0001-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/3f21f1c4-4de7-4131-af58-bb484abd6473/jcpt12404-toc-0001-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![PDF) CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of 'Spin' In Scientific Writing | Jan M Keppel Hesselink - Academia.edu PDF) CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of 'Spin' In Scientific Writing | Jan M Keppel Hesselink - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/52203122/mini_magick20190123-10100-ml9k8j.png?1548261904)